Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis

被引：0
|
作者：
Shih, J-Y. [1 ]
Wang, J. [2 ,4 ]
Wang, Y. [3 ]
Wang, J. [2 ,4 ]
Lee, S-H. [5 ]
Azuma, K. [6 ]
Takahashi, T. [7 ]
Tan, J-L. [8 ]
Lin, C. C. [9 ]
Ganguly, S. [10 ]
Lee, V. H. F. [11 ]
Chu, P-L. [12 ]
Shah, S. [13 ]
Diorio, B. [14 ]
Bauml, J. M.
Cho, B. C. [15 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[2] Chinese Acad Med Sci & Peking Union Med Coll, Med Oncol Dept, Beijing, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Thorac Oncol, Ctr Canc, Chengdu, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan
[7] Shizuoka Canc Ctr, Div Thorac Oncol, Nagaizumi, Shizuoka, Japan
[8] Univ Malaya, Dept Med, Kuala Lumpur, Malaysia
[9] Natl Cheng Kung Univ, Coll Med, Dept Internal Med, Tainan, Taiwan
[10] Tata Med Ctr, Med Oncol Dept, Kolkata, India
[11] Univ Hong Kong, LKS Fac Med, Sch Clin Med, Dept Clin Oncol, Hong Kong, Peoples R China
[12] Janssen R&D, Raritan, NJ USA
[13] Janssen R&D, Spring House, PA USA
[14] Janssen R&D, Titusville, NJ USA
[15] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA11
引用
收藏
页码：S1661 / S1662
页数：2
相关论文
共 50 条
  • [1] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Passaro, A.
    Wang, J.
    Wang, Y.
    Lee, S. -H.
    Melosky, B.
    Shih, J. -Y.
    Wang, J.
    Azuma, K.
    Juan-Vidal, O.
    Cobo, M.
    Felip, E.
    Girard, N.
    Cortot, A. B.
    Califano, R.
    Cappuzzo, F.
    Owen, S.
    Popat, S.
    Tan, J. -l.
    Salinas, J.
    Tomasini, P.
    Gentzler, R. D.
    William, W. N.
    Reckamp, K. L.
    Takahashi, T.
    Ganguly, S.
    Kowalski, D. M.
    Bearz, A.
    MacKean, M.
    Barala, P.
    Bourla, A. B.
    Girvin, A.
    Greger, J.
    Millington, D.
    Withelder, M.
    Xie, J.
    Sun, T.
    Shah, S.
    Diorio, B.
    Knoblauch, R. E.
    Bauml, J. M.
    Campelo, R. G.
    Cho, B. C.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (01) : 77 - 90
  • [2] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Moik, F.
    Riedl, J. M.
    Ay, C.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (03) : 327 - 327
  • [3] Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Passaro, A.
    Wang, J.
    Shah, S.
    Bauml, J. M.
    Campelo, R. G.
    Cho, B. C.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (03) : 328 - 329
  • [4] Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
    Passaro, A.
    Cho, B. C.
    Wang, Y.
    Melosky, B.
    Califano, R.
    Lee, S-H.
    Girard, N.
    Reckamp, K. L.
    Takahashi, T.
    Felip, E.
    Gentzler, R. D.
    Popat, S.
    William, W. Nassib, Jr.
    Sun, T.
    Shah, S.
    Diorio, B.
    Knoblauch, R. E.
    Bauml, J. M.
    Garcia-Campelo, M. R.
    Wang, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1307 - S1307
  • [5] MARIPOSA-2: Randomized phase III study of amivantamab plus lazertinib plus chemotherapy vs chemotherapy alone in EGFRmutant NSCLC after osimertinib failure
    Wang, J.
    Garcia Campelo, R.
    Girard, N.
    Leighl, N.
    Reckamp, K.
    Takahashi, T.
    Li, S.
    Millington, D.
    Barala, P.
    Bauml, J. M.
    Knoblauch, R. E.
    Cho, B. C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1597 - S1597
  • [6] Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC
    Piotrowska, Zofia
    Liu, Stephen V.
    Muzikansky, Alona
    Marcoux, Nicolas
    Banwait, Mandeep
    Stevens, Sara
    Goodwin, Kelly
    Lafferty, Tracey E.
    Ackil, Jennifer
    Krueger, Elizabeth A.
    Heist, Rebecca Suk
    Lin, Jessica Jiyeong
    Gainor, Justin F.
    Hata, Aaron N.
    Shaw, Alice Tsang
    Sequist, Lecia V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
    White, Maya N.
    Piotrowska, Zofia
    Stirling, Kevin
    Liu, Stephen V.
    Banwait, Mandeep K.
    Cunanan, Kristen
    Sequist, Lecia V.
    Wakelee, Heather A.
    Hausrath, Daniel
    Neal, Joel W.
    [J]. CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
  • [8] Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
    White, Maya N.
    Piper-Vallillo, Andrew J.
    Gardner, Rebecca M.
    Cunanan, Kristen
    Neal, Joel W.
    Das, Millie
    Padda, Sukhmani K.
    Ramchandran, Kavitha
    Chen, Thomas T.
    Sequist, Lecia, V
    Piotrowska, Zofia
    Wakelee, Heather A.
    [J]. CLINICAL LUNG CANCER, 2022, 23 (03) : E210 - E221
  • [9] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [10] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
    Shreeve, S. M.
    Martinez, M.
    Verheijen, R. B.
    Xie, J.
    Sun, T.
    Haddish-Berhane, N.
    Curtin, J. C.
    Karkera, J.
    Pang, D.
    Roshak, A.
    Knoblauch, R. E.
    Patel, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
12345